FDA is effectively enabling and assisting doctors and hospitals filing eINDs for Leronlimab to get access, and allowing the existing trial sites to continue “open label expansion”... they can continue using Leronlimab to treat severe / critical patients (those who would qualify for cd12) and collect additional data.
Edit - sorry, thought new hospitals and docs would effectively be new trial sites, not the case.